Eisai Inc.
Global Headquarters:
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 Japan
US Headquarters: 100 Tice Blvd.
Woodcliff Lake
New Jersey
07677
United States
525 articles about Eisai Inc.
-
Eisai Inc. Release: FYCOMPA (Perampanel) Oral Suspension Now Available As An Option For Patients With Epilepsy Who May Have Difficulty Swallowing Tablets Or Prefer Liquids
6/15/2016
-
Eisai Inc. And Lennox-Gastaut Syndrome (LGS) Foundation Convened Experts To #HackLGS
6/15/2016
-
Eisai Inc. Enters Into A Collaboration Agreement To Co-Promote LENVIMA (Lenvatinib) In Combination With Everolimus In The U.S.
6/3/2016
-
AbbVie And Eisai Inc. Subsidiary EA Pharma Commence Co-promotion Of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA In The Field Of Gastrointestinal Disease
6/1/2016
-
FDA Approves Eisai Inc.'s LENVIMA (Lenvatinib) For The Treatment Of Patients With Advanced Renal Cell Carcinoma In Combination With Everolimus Following Prior Anti-Angiogenic Therapy
5/16/2016
-
Dr. Avinash Desai Appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group At Eisai Inc.
4/20/2016
-
Eisai Inc. Release: Paul Hawthorne Appointed Senior Vice President, U.S. Commercial, Neurology Business Group At Eisai Inc.
4/6/2016
-
Data On Eisai Inc.'s Halaven (eribulin mesylate) Injection In Advanced Liposarcoma Published In The Lancet
2/11/2016
-
Eisai Inc.'s Lenvatinib Receives FDA Priority Review For The Potential Treatment Of Advanced Renal Cell Carcinoma In Combination With Everolimus
1/18/2016
-
Eisai Inc. Presents Data On Perampanel And First And Largest U.S. Study On Caregiver Burden In Epilepsy At The 69th Annual American Epilepsy Society Meeting
12/2/2015
-
Eisai Inc. And Arena Announce Completion Of Enrollment In BELVIQ (lorcaserin HCI) CAMELLIA-TIMI 61 Study
12/1/2015
-
Helsinn Group And Eisai Inc. Announce Inclusion Of AKYNZEO (netupitant/palonosetron) In ASCO Antiemetics Guideline Update
11/13/2015
-
Eisai Inc. Signs Research Collaboration Agreement With The Paoli Calmettes Institute
11/4/2015
-
Eisai Inc. And Arena Announce Presentation Of Lorcaserin Hcl Data At 2015 Annual Obesity Week Meeting
11/2/2015
-
Eisai Inc. Release: Halaven (eribulin mesylate) Injection Nominated For Best Pharmaceutical Agent Of The Year At The Prix Galien USA Awards
10/26/2015
-
Results of Hematology/Oncology Pharmacy Association And Eisai Inc. Survey Show 83 Percent Of Patients Receiving Chemotherapy May Be Unnecessarily Suffering From Chemotherapy-Induced Nausea And Vomiting
10/19/2015
-
Eisai Inc. Presents New Analyses Of Lenvatinib Data At The International Thyroid Congress (ITC)
10/15/2015
-
Eisai Inc. Release: New Myths And Truths About Thyroid Cancer Education Initiative Aims To Shine A Light On The Truths About Thyroid Cancer
9/15/2015
-
Eisai Inc. Announces FDA Acceptance Of NDA For The Review Of FYCOMPA (perampanel) Oral Suspension For Adjunctive Therapy In The Treatment Of Partial-Onset Seizures And Primary Generalized Tonic-Clonic Seizures In Patients With Epilepsy Age 12 And Older
9/14/2015
-
Ivor Macleod Appointed Senior Vice President, Chief Financial Officer And Chief Compliance Officer Of Eisai Inc.
6/1/2015